Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

First subject enrolled in phase III study of TRC-101 in chronic kidney disease

Sep. 29, 2017

The Brigham and Women's Hospital identifies SMOC2 inhibitors

Sep. 26, 2017

FDA accepts for review sNDA for mirabegron in combination with solifenacin for overactive bladder

Sep. 14, 2017

Bayer enters kidney disease collaboration with Vanderbilt University Medical Center

Sep. 12, 2017

MK-3866 studied in patients with impaired renal function

Sep. 12, 2017

Avadel enters license agreement for U.S. and Canadian rights to Noctiva

Sep. 6, 2017

Enrollment completed in phase IIb study of BGS-649 for hypogonadotropic hypogonadism

Sep. 5, 2017

Taisho Pharmaceutical presents 20-HETE synthase inhibitors

Sep. 1, 2017

Apricus resubmits Vitaros NDA

Aug. 30, 2017

Anthera reports topline data from BRIGHT-SC extension of blisibimod in IgA nephropathy

Aug. 30, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...